Some experts say we’re in “the golden age of biotechnology.” Scientific advances are opening up possibilities for the treatment and prevention of diseases that could only have been imagined in the past. This golden age is also presenting tremendous opportunities for investors.
Biotech stocks offer the potential for substantial long-term returns. The best biotech stocks to buy right now boast robust pipelines, and some already have winning drugs on the market. Our pick for the day ticks all of these boxes.
A company with 400 million ‘patents’
One company has quietly compiled more than 400 million official trade secrets.
Trade secrets are like patents in that they protect valuable and proprietary information…
But unlike patents, trade secrets take less time to register… and more importantly, they never expire.
Which is a huge advantage for this little-known company.
You see, this company is using these trade secrets to build the world’s largest “codebase,” which will bethe key to it becoming “America’s Next Big Monopoly.”
Not surprisingly, Wall Street is starting to take notice. And the smart money is already pouring in.
Tech investor Cathie Wood has invested over $80 million already, and Microsoft founder Bill Gates has invested as well.
Get the details here before this story hits the mainstream media.
Vertex Pharmaceuticals (VRTX) is the undisputed leader in cystic fibrosis therapies. The company’s portfolio of approved CF drugs will deliver at least an estimated $8.4 billion this year, made possible by intense market penetration and decades-long devotion to research and development in the space.
So far, the company has managed to remain strongly profitable and has continued to expand revenue within the CF market at a steady pace. If management’s plans for expanded approvals for younger cohorts continue to come to fruition over the next few years, Vertex will eventually treat as many as 90% of all people with CF.
The company is moving its pipeline beyond CF with a handful of mid-stage clinical programs for pain relief, kidney disease, and hematologic genetic disorders like sickle cell disease. In other words, even if it eventually corners the entire CF therapies market, there will still be other growth opportunities.
[stock_market_widget type=”accordion” template=”extended” color=”#5679FF” assets=”VRTX” start_expanded=”true” display_currency_symbol=”true” api=”yf”]